Clinical Trials Browser

Phase 1/2 × Lisaftoclax × Plasma cell × Clear all

NCT04942067 2023-10-25

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Amyloidosis, Multiple Myeloma

NCT04674514 2023-03-07

APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma